Portfolio company
KSQ Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops gene-edited cell therapies and small molecule medicines for oncology patients and pharmaceutical partners using a functional genomics discovery platform.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Light Horse
This company develops small molecule therapeutics for oncology patients using a genome editing platform to identify functional sites on protein targets.
Ensoma
This company develops in vivo genomic medicines and vector delivery platforms to engineer blood and immune cells for patients with genetic diseases and cancer.
Tessera
The company develops genome engineering platforms to write therapeutic DNA sequences into cells for clinicians and researchers treating genetic diseases.
Beam Therapeutics
The company develops precision genetic medicines using base editing technology to treat patients with serious genetic diseases such as sickle cell disease.
Transforming cells into cures
This company develops a cellular engineering platform to design and optimize cell therapies for biopharmaceutical developers and research institutions.
Alia Therapeutics
The company develops gene editing medicines for patients with genetic diseases.
EDITAS Medicine
The company develops CRISPR-based genome editing medicines to treat patients with serious genetic diseases, including blood disorders and inherited eye conditions.
Kodikaz Therapeutics
Kodikaz Therapeutics develops a cell-specific non-viral delivery platform for targeted gene therapies to treat various cancers for patients and healthcare providers.